摘要
阿尔茨海默病(AD)是一种进行性神经退行性疾病。β淀粉样蛋白(Aβ)沉积和过度磷酸化的Tau蛋白形成的神经原纤维缠结(NFT)是该病的病理学特征。在过去的20年中,分子影像探针在AD的诊疗中取得了很大进展,其作用已经超越了传统的脑灌注和葡萄糖代谢显像。与Aβ或NFT特异性结合的分子影像探针可成为准确和早期诊断AD的有价值工具,且其已被提出作为最近修订的临床诊断标准中的生物标志物。笔者主要对Aβ和NFT分子影像探针的研究进展进行综述。
Alzheimer disease(AD)is a progressive neurodegenerative disease.Amyloid beta-peptides(Aβ)deposition and neurofibrillary tangles(NFT)formed by hyperphosphorylated Tau protein are the pathological features of the disease.In the past two decades,molecular imaging probes have made great progress in the diagnosis and treatment of AD,and have perfomred the important role beyond traditional cerebral perfusion and glucose metabolism imaging.Molecular imaging probes which specifically bind to Aβor NFT can become valuable tools for accurate and early diagnosis of AD,and have been proposed as biomarkers in the recently revised clinical diagnostic criteria.In this paper,the research status and advances of Aβand NFT molecular imaging probes are reviewed.
作者
宗佳滨
兰晓莉
张永学
Zong Jiabin;Lan Xiaoli;Zhang Yongxue(Department of Nuclear Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Province Key Laboratory of Molecular Imaging,Wuhan 430022,China)
出处
《国际放射医学核医学杂志》
2022年第1期35-41,共7页
International Journal of Radiation Medicine and Nuclear Medicine
